Aktis Oncology AKTS Insider Ownership

NASDAQ AKTS

$15.73 +0.00 (+0.00%)

At close: Oct 26, 2026 · 4:00 PM EDT

Insider Holdings by Owner

25.52Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

27.32%

■0% pp QoQ

Shares Held by Insiders

15.11Mn

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

55.30Mn

55,300,107 shares

Direct Holdings

Indirect: 15.11Mn

Net Open-Market Trades

-120.42K

net sold · -$3.23Mn in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Open-Market Insider Trades

Bought Sold

Latest quarter —

Net over range —

Net-buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Aktis Oncology insiders totaled $79.25 million in purchases (4.4Mn shares) and $3.23 million in sales (120.42K shares).

Aktis Oncology's open-market purchases in the past 12 months came from 4 insiders, and its sales from 3 insiders.
Among AKTS insiders, Ecor1 Capital, LLC (Director) bought the most stock on the open market in the past 12 months: $40 million (2.22Mn shares), most recently on January 12, 2026.
Conversely, Akos Czibere (Chief Medical Officer) was AKTS's largest open-market seller in the past 12 months, with $1.65 million of sales (62.5K shares); the latest was on September 23, 2026.
In transactions other than open-market trades, Aktis Oncology insiders acquired 20.54Mn shares through option exercises and conversions over the past 12 months.
Business Quant data shows Aktis Oncology insiders holding 15.11Mn shares in total in their latest Form 4 filings, unchanged from 15.11Mn shares at the end of Q2 2026.
Aktis Oncology insiders report no direct holdings: all 15.11Mn shares are held indirectly.
Business Quant counts 5 insiders with holdings in Aktis Oncology stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
AKTS's largest insider holders by reported holdings are MPM Bioventures 2018, L.P. (10% owner, 10.26Mn shares), Todd Foley (Director and 10% owner, 4.24Mn shares) and Ecor1 Capital, LLC (Director, 433.53K shares).
The largest insider, MPM Bioventures 2018, L.P., holds 67.92% of AKTS's insider total.
Institutional holders reported 61.80% of Aktis Oncology's outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 27.32%, and other investors, including the public, hold the remaining 10.88%.
In the past year, 11 insiders of Aktis Oncology submitted 13 Form 4 filings reporting trades, awards or other transactions.
The insider data for AKTS reflects Form 4 filings through September 24, 2026.

Form 4 Holdings

Insiders Holding AKTS

Insiders 7

Shares held 25.52Mn

Of outstanding 46.15%

#	Insider	Position	Indirect	Total	Share of Insiders	Last Filed
1	Ansbert Gadicke	TenPercentOwner	10,260,064	10,260,064	40.2%	14 Jan, 2026
2	Bioventures 2018, L.P. Mpm	TenPercentOwner	10,260,064	10,260,064	40.2%	14 Jan, 2026
3	Todd Foley	Director, TenPercentOwner	4,235,403	4,235,403	16.6%	14 Jan, 2026
4	Capital, Llc Ecor1	Director	433,527	433,527	1.7%	12 Jan, 2026
5	Ventures Ii, Llc Vida	TenPercentOwner	157,387	157,387	0.6%	12 Jan, 2026
6	Helen Susan Kim	Director, TenPercentOwner	157,387	157,387	0.6%	12 Jan, 2026
7	Lloyd Mitchell Segal	Director	19,631	19,631	0.1%	12 Jan, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

76 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
23 Sep, 2026	Akos Czibere	Chief Medical Officer	Acquired M	12,500	$4.95	$61.88K	12,500	Direct
23 Sep, 2026	Akos Czibere	Chief Medical Officer	Disposed S	5,099	$20.19	$102.97K	7,401	Direct
23 Sep, 2026	Akos Czibere	Chief Medical Officer	Disposed S	7,401	$21.03	$155.65K	0	Direct
23 Sep, 2026	Akos Czibere	Chief Medical Officer	Disposed M	12,500	$0.00	$0	208,718	Direct
20 Jul, 2026	Ken Herrmann	Director	Acquired M	3,506	$0.08	$280	3,506	Direct
20 Jul, 2026	Ken Herrmann	Director	Acquired M	1,350	$1.91	$2.58K	4,856	Direct
20 Jul, 2026	Ken Herrmann	Director	Disposed S	3,506	$24.56	$86.12K	1,350	Direct
20 Jul, 2026	Ken Herrmann	Director	Disposed S	1,350	$24.56	$33.16K	0	Direct
20 Jul, 2026	Ken Herrmann	Director	Disposed M	3,506	$0.00	$0	0	Direct
20 Jul, 2026	Ken Herrmann	Director	Disposed M	1,350	$0.00	$0	18,364	Direct
17 Jul, 2026	Ken Herrmann	Director	Acquired M	3,065	$0.08	$245	3,065	Direct
17 Jul, 2026	Ken Herrmann	Director	Disposed S	3,065	$25.21	$77.26K	0	Direct
17 Jul, 2026	Ken Herrmann	Director	Disposed M	3,065	$0.00	$0	3,506	Direct
08 Jul, 2026	Shulamit Ron-Bigger	Chief Operating Officer	Acquired M	50,000	$3.66	$183.00K	50,000	Direct
08 Jul, 2026	Akos Czibere	Chief Medical Officer	Acquired M	50,000	$4.95	$247.50K	50,000	Direct
08 Jul, 2026	Shulamit Ron-Bigger	Chief Operating Officer	Disposed S	15,800	$27.13	$428.68K	34,200	Direct
08 Jul, 2026	Akos Czibere	Chief Medical Officer	Disposed S	14,800	$27.13	$401.48K	35,200	Direct
08 Jul, 2026	Akos Czibere	Chief Medical Officer	Disposed S	30,829	$27.95	$861.74K	4,371	Direct
08 Jul, 2026	Shulamit Ron-Bigger	Chief Operating Officer	Disposed S	30,000	$27.94	$838.14K	4,200	Direct
08 Jul, 2026	Shulamit Ron-Bigger	Chief Operating Officer	Disposed S	4,200	$28.75	$120.74K	0	Direct

Showing 1 to 20 of 76 transactions